Market withdrawal of new molecular entities approved in the United States from 1980 to 2009
about
A mechanistic, model-based approach to safety assessment in clinical developmentThe ChEMBL database in 2017A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment.Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data.Exploration of Biomarkers for Amoxicillin/Clavulanate-Induced Liver Injury: Multi-Omics Approaches.Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group.Genetic, clinical and pharmacological determinants of out-of-hospital cardiac arrest: rationale and outline of the AmsteRdam Resuscitation Studies (ARREST) registryEvolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges.Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals.Pharmacovigilance in oncology: evaluation of current practice and future perspectives.Actions following adverse drug events - how do these influence uptake and utilisation of newer and/or similar medications?Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytesAutomated Electrophysiological and Pharmacological Evaluation of Human Pluripotent Stem Cell-Derived Cardiomyocytes.And if the discovery of new drugs for the treatment of brain diseases depends on Asian countries?Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods.Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform.Application of urine proteomics for biomarker discovery in drug-induced liver injury.Novel pre-clinical methodologies for pharmacokinetic drug-drug interaction studies: spotlight on "humanized" animal models.The role for microRNAs in drug toxicity and in safety assessment.Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone.Cardiotoxicity screening: a review of rapid-throughput in vitro approaches.A new era of disease modeling and drug discovery using induced pluripotent stem cells.De Novo Human Cardiac Myocytes for Medical Research: Promises and Challenges.MicroRNAs in injury and repair.Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009.Benefit-risk reassessment of medicines: a retrospective analysis of all safety-related referral procedures in Europe during 2001-2012.Approving molecularly targeted drugs: different approval processes for cytotoxic agents.Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study.[Pharmacovigilance in Germany : It is about time].Translational bioinformatics: data-driven drug discovery and development.Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases.Development of cardiac safety translational tools for QT prolongation and torsade de pointes.A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France.Dose-dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitor.Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.Application of Proteomic Approaches to Accelerate Drug Development for Psychiatric Disorders.MicroRNAs as biomarkers for clinical studies.Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions.Plasma miR-208 as a useful biomarker for drug-induced cardiotoxicity in rats.Necessary, but Not Sufficient. The Benefit Concept in the Project Evaluation of Animal Research in the Context of Directive 2010/63/EU.
P2860
Q28395802-EDF64094-1E40-471E-B616-22E8AA9E8E7CQ28584450-EDE33167-8F40-43ED-82EF-275E8ACD7AEDQ30812957-2D1487C8-8F6C-4E49-9E28-71C9891F2D2FQ31114073-7918C566-CAA6-4DD2-8C24-F20A32269FEFQ33648066-1C1538B8-E4F9-4886-91F6-BA42F49296CAQ33790423-2FB7EE2F-635B-465B-8023-13408494232EQ34304828-B4E9724B-FE0B-4E87-81B1-87300962AA90Q34417044-598EB92B-39EB-4A4F-9101-20232C7057C6Q34442025-33E798D2-03A5-4429-B2F5-84EDB3B64F3CQ35183601-26CCEBB9-13B0-41F6-96E9-981916318EB8Q35834675-55C70863-38AC-4703-B628-4CDE22212353Q36365384-783047E5-5593-4977-AD9A-0E249F4FD020Q36683233-80732435-4CDC-4265-B73C-31CEDF1BCF95Q36897714-12B1EA70-93DF-46A9-906C-F2C95333988FQ37354917-F792E49C-32C1-4646-89C5-1F1010033A6CQ37573646-CCB52257-78FE-4B5B-80B3-0958FCAF4506Q38255178-F0D65D79-40D7-47D6-A2DF-78A4B8E3A590Q38255685-D593572A-CA61-4A32-AEB7-70F1522F2D1DQ38367620-A62A2066-AFF4-4AE5-B36E-7465C6885E76Q38587979-10F30C09-6608-489E-A961-DBFA0D8B1288Q38671689-E0730B3D-A449-4EE5-84EF-6DC2D2FFCFDBQ38786732-2526384E-80D6-429D-A751-182F7DB25C05Q39183022-AD63994D-EB5B-4641-A108-94523A7672EAQ39304689-988F2025-BD15-4D12-A2C1-9106AE8647F5Q39340620-E6F3DFB8-4367-4E2E-9ED3-AE9DEFECC56CQ39794630-D3B036F8-D9DC-4755-9680-B9355CD5215FQ39829792-084EBF05-7E07-4CE9-9DC6-A36B0E4612E8Q40604485-B967976B-385E-479B-9383-516927C1A05AQ40736061-FFCBC858-E021-4665-A196-058D391D37A5Q42649041-5A185EA9-50E4-4F64-839D-79A23A27DBC0Q44428648-0FBD3C9B-E474-47C7-B9C4-0B2462662AB0Q45741579-9840DE5A-524A-4166-972D-1FD5DEF210EDQ46200243-3020C73A-DA54-4BA1-930A-736D07232B7BQ47565453-16B4DBDB-63DA-49BF-9E62-C72490424A21Q47611653-18A852EB-B959-4405-9E91-FA478AE9CFB4Q47763396-9D915FD5-1906-4B64-BDA5-1B7EF1247160Q47947610-14A0AB24-1457-4283-B20F-B668AAD24928Q52614686-30318C72-696E-4A62-870A-952F6B8A4472Q54195804-D3E43EC8-EBFA-4169-A9A0-9967D78BC040Q55082366-305F89FE-6DD1-4275-BDBE-AA8BBDD5B07A
P2860
Market withdrawal of new molecular entities approved in the United States from 1980 to 2009
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Market withdrawal of new molec ...... nited States from 1980 to 2009
@ast
Market withdrawal of new molec ...... nited States from 1980 to 2009
@en
Market withdrawal of new molec ...... nited States from 1980 to 2009
@nl
type
label
Market withdrawal of new molec ...... nited States from 1980 to 2009
@ast
Market withdrawal of new molec ...... nited States from 1980 to 2009
@en
Market withdrawal of new molec ...... nited States from 1980 to 2009
@nl
prefLabel
Market withdrawal of new molec ...... nited States from 1980 to 2009
@ast
Market withdrawal of new molec ...... nited States from 1980 to 2009
@en
Market withdrawal of new molec ...... nited States from 1980 to 2009
@nl
P2093
P2860
P356
P1476
Market withdrawal of new molec ...... nited States from 1980 to 2009
@en
P2093
Enrique Seoane-Vazquez
Kurt B Stevenson
Rosa Rodriguez-Monguio
Sheryl L Szeinbach
Zaina P Qureshi
P2860
P356
10.1002/PDS.2155
P407
P577
2011-07-01T00:00:00Z